Specialty Pharmacy

HIV drug Tenofovir may carry a risk of nephrotoxicity.

Top stories of the week on Specialty Pharmacy Times.

Osimertinib (Tagrisso) is a once daily tablet for patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.

Hormone treatment may prove to be effective alternative option for patients with invasive lobular carcinoma.

MS cognitive screening tool able to predict actual functional performance.

Treatment with sarilumab improves RA signs, symptoms, and physical function.

Patients simultaneously registering at multiple centers had higher transplant rates, lower death rates waiting for a transplant, and greater income.

Ixekizumab found to improve skin clearance of plaque psoriasis and reduced disability when performing certain physical functions.

Questions still persist regarding immunologic mechanisms of MS treatments and vitamin D.

Initiative does not prohibit the purchase or sale of private coverage duplicating the public plan.

The FDA has accepted for review Amgen's new drug application for etelcalcetide to treat secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis.

Pharmacy interventions for patients taking new medications can improve adherence, reduce health care costs, and improve outcomes.

Cosentyx found to maintain improvements in joint and skin disease, physical function, and quality of life in PsA patients.

Patients with cancer see a decline in employment, hours worked, individual income, and total family income following diagnosis.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the development of medical marijuana within the specialty space.

HCV drug combination may cut treatment time by 75%.

New payment models hold care providers accountable for the full spectrum of patient care.

Baricitinib improved disease activity in patients not responding to conventional or biologic DMARDs.

Combination of Cotellic and Zelboraf shows superior overall and progression free survival in melanoma treatment.

Newly discovered pathway may prove effective target for treatment of triple-negative breast cancer.

Direct-acting antivirals may help eradicate hepatitis C virus in patients who recently had a liver transplant, reducing the need for further transplants.

Biosimilar may offer patients with RA drug cost relief in the near future.

Genetic information may help develop treatment guidelines for Crohn's disease and ulcerative colitis.

Patients with diabetes fare better after surgery when pharmacists manage their high blood sugar.

Micro RNA based blood test may be used with imaging features to accurately predict disease severity.

Once-a-week treatment is the first oral proteasome inhibitor to reach late stage clinical development.

Michael Zeglinski, vice president of Specialty Pharmacy Operations at BriovaRx, discusses the alignment between specialty pharmacies and ACOs.

Benefits of Plavix found to outweigh potential adverse events.